Explore Retatrutide/Tirzepatide Blend dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
Retatrutide/Tirzepatide Blend is a research-only combination sourced for weight-loss and metabolic studies that stack two of the most-studied incretin agonists — Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist retatrutide and the approved dual GIP/GLP-1 agonist tirzepatide. No sponsor develops the pairing; it ships as lyophilized powder you reconstitute with bacteriostatic water before use.[1][2]
Both molecules share GIP and GLP-1 receptor agonism, so the blend stacks two overlapping incretin signals rather than two complementary ones; retatrutide adds a glucagon-receptor arm that tirzepatide lacks, which is the only mechanistically novel element the combination contributes over high-dose retatrutide alone.[1][3]
No clinical trial of the retatrutide + tirzepatide combination has been published, and no sponsor is developing it. The two molecules are studied only separately — retatrutide in the TRIUMPH Phase 3 program and tirzepatide in the SURPASS and SURMOUNT programs — and because their GIP and GLP-1 mechanisms overlap, stacking them is not the same as combining two independent pathways.[1][2][3]
Retatrutide is investigational and not FDA-approved; tirzepatide is FDA-approved (Mounjaro/Zepbound) but the fixed-ratio blend is in no sponsor pipeline. Research-grade material only.
Retatrutide/Tirzepatide Blend is a blend of Retatrutide and Tirzepatide, so a reconstitution figure for it covers the combined vial contents rather than any single component. It is catalogued under Weight Loss on WPA.
361 Retatrutide/Tirzepatide Blend reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.